AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06665282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed high intensity laser therapy
Description: The study employs a BTL-6000 high-intensity laser therapy (12 W) to apply high intensity laser therapy to deep tissues. high intensity laser therapy therapy uses powerful beams (>500 mw) to penetrate deeper, delivering high multi-directional energy in a short time. Pulsed laser therapy, a form of high intensity laser therapy therapy, enhances cell metabolism without disrupting it.~High-intensity laser therapy is a safe treatment method consisting of three phases. The first phase involves fast scanning around the wrist, hand, and fingers, with fluencies set at 510, 610, and 710mJ/cm2. The second phase involves holding the handpiece vertically to 90° on 10 fixed points around the metacarpophalangeal and interphalangeal joints, each radiated for 15 seconds, and a total dose of 1500 J. The third phase is the same but at a slower rate, with a total energy of 300 J.
Study NCT05549258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Description: Inebilizumab administered intravenously (IV) over a total of 28 weeks.
Study NCT04603898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Oxalate Diet
Description: Subjects will be instructed to ingest a controlled diet low in oxalate for a total of 4 days
Study NCT04603898 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbon-13 Ascorbic Acid Oral Load
Description: Subjects will be instructed to ingest 1mg/kg of carbon-13 ascorbic acid at breakfast, 2 days after initiating the low oxalate controlled diet.
Study NCT04024917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac coherence
Description: An initiation session to cardiac coherence will take place D-11 before the operation (during the surgical consultation) in order to obtain a breathing rate of 6 cycles/min via a free application (Respirelax) with listening to an audio tape.~3 cardiac coherence sessions per day of 5 min (before meals) during the 11 days preceding the operation.~- The program cardiac coherence will be performed during 90 days after the surgery
Study NCT06665282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sham pulsed high intensity laser therapy
Description: Patients in the control group will receive sham high-intensity laser therapy, where all parameters will be set up without switching on the start button and high intensity laser therapy machine is switched on with a visible light beam only
Study NCT04024917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care
Study NCT06665282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy program
Description: All patients of the study and control groups will receive the same routine physical therapy program for 30minutes and three times per week for successive eight weeks in the form of hot therapy, stretching and strengthening exercises. Hot therapy, in the form of warm baths for 10minutes, is applied before stretching exercises on the wrist joint and fingers to relieve joint pain and increase the range of motion. Strengthening exercises are in the form of isometric exercise for hand muscles and fingers to maintain muscles strength and joints flexibility
Study NCT00733694 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LCS® Complete™ Mobile Bearing Knee Systems
Description: An orthopaedic implant for primary total knee replacement with a mobile bearing knee
Study NCT06665282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy program
Description: All patients of the study and control groups will receive the same routine physical therapy program for 30minutes and three times per week for successive eight weeks in the form of hot therapy, stretching and strengthening exercises. Hot therapy, in the form of warm baths for 10minutes, is applied before stretching exercises on the wrist joint and fingers to relieve joint pain and increase the range of motion. Strengthening exercises are in the form of isometric exercise for hand muscles and fingers to maintain muscles strength and joints flexibility
Study NCT06667349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 90 mg PO BID given for atleast two weeks following primary PCI
Study NCT06667349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 90 mg PO BID given for atleast two weeks following primary PCI
Study NCT06668688 — intervention group
Intervention type: DEVICE
Intervention: ich bin alles @Schule (i am everything @school; www.schule.ich-bin-alles.de)
Description: The web-based information platform for educational professionals ich bin alles @Schule (i am everything @school; www.schule.ich-bin-alles.de) on depression and mental health in childhood and adolescence was developed by the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the LMU Munich Hospital together with the Prof. Otto Beisheim Foundation. The website is intended to provide low-threshold information about depression and mental health in the school context.
Study NCT05498428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously by manual injection.
Study NCT06668038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary and multicenter validation of re-irradiation with curative intent
Description: Validation in multidisciplinary and multicenter meeting of re-irradiation indication after review of technical data (images, structures and doses) of 1st irradiation and recent diagnosis images of the lesion to be irradiated, merged using MIM.~In case of re-irradiation validation, validation in multidisciplinary and multicenter meeting of cumulated doses after review of EQD2 doses summation using MIM.
Study NCT06665854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic Song Group
Description: The rhythmic song group will first click on the start button on the mobile application. When starting the application to stimulate the baby, a bell will ring, and the baby movements will be coded as present/absent via the mobile application; then they will sing a rhythmic song and recode the baby movements as present/absent via the mobile application. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week.
Study NCT06665854 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic Instrument Group
Description: The Rhythmic Instrument Group will first click on the start button on the mobile application. Then, they will ring a bell to start the application to warn the baby, and they will code the baby's movements as present/absent via the mobile application; then they will play a rhythmic instrument and code the baby's movements as present/absent via the mobile application again. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week.
Study NCT06665854 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Control Group will first code Start via the mobile application. Then, a bell will ring to warn the baby, they will code the baby's movements as present/absent via the mobile application again and will only rest. When the application is over, all pregnant women will code Finish via the mobile application. Applications will begin in the 28th week of pregnancy and continue until the 37th week of pregnancy. Pregnant women will receive rhythm therapy applications for 20 minutes twice a week.
Study NCT06667050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus sintilimab and bevacizumab
Description: Laparoscopic exploration should be performed to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum.~3 cycles of neoadjuvant therapy will be administered: capecitabine: 100 mg/m2, Bid, d1-14, q3w; oxaliplatin: 130 mg/m2, iv drip, d1, q3w; sintilimab: 200 mg, iv drip, d1, bevacizumab biosimilar (IBI305) 10mg~/Kg, iv drip, d1, q3w. Radical D2 gastric cancer resection will be performed within 6-8 weeks after the last administration of chemotherapy plus sintilimab and bevacizumab biosimilar (IBI305).~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with CAPOX regimen for up to 3 cycles.
Study NCT06668766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10-cm Single Lumen Mildine
Description: Arm Description: The BD Powerglide Pro Midline catheter is currently approved for use by the FDA and by Albany Medical Center. This 18-gauge or 20-guage MC is distinct in that it is a standard 10-cm, does not require premeasurement or trimming of the catheter prior to placement, and features an accelerated Seldinger technique, meaning that it has a built-in deployable internal wire system. Additionally, because it is only 10-cm, it does not require a confirmatory chest x-ray prior to use. The provider will use standard aseptic technique for placing the MC (e.g., chlorhexidine prep, sterile probe cover and gel). Once the target vessel is identified, an ultrasound image of the vessel will be captured and recorded with the subject's study ID number from the randomization packet to allow for vessel depth and size measurement.
Study NCT06668766 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 4.78 cm Long Peripheral Intravenous Catheter
Description: The BD Insyte Autoguard 4.78 cm 18- or 20-gauge needle with self-retraction is currently approved for use by the FDA and by Albany Medical center. The long PIV will be placed using standard aseptic technique (e.g., chlorhexidine prep, sterile gloves, sterile ultrasound probe cover and gel). Once the target vessel is identified, an ultrasound image of the vessel will be captured and recorded with the subject's study ID number in the comments section of the QPATH worksheet to allow for vessel depth and size measurement. Operators will be instructed to use standard techniques in US-guided vascular access.
Study NCT06666062 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: implant placement and low level laser therapy
Description: Laser biomodulation with low level laser therapy around delayed implant
Study NCT06666062 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: implant placement
Description: Delayed implant placement restoring missed tooth
Study NCT05498428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Lazertinib will be administered as an oral tablet.
Study NCT06667258 — intervention group
Intervention type: DEVICE
Intervention: Ear ECG/PPG sensors
Description: Medical graded electrodes placed in the mastoid, in-ear foam-based earpiece (like commercial earplugs) with cloth electrodes, off-the-shelf pulse oximeter placed behind the ear
Study NCT06619314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral Tablet
Study NCT03614351 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein (PROT)
Description: Participants will receive Combat Protein Powder made by MusclePharm in an amount sufficient to take 80g daily until their next visit. They will be encouraged to ingest 40 g after exercise and 40 g before bed which will partly comprise their daily goal. They will be educated on the concept of complete high quality proteins, and that some proteins can facilitate muscle growth greater than others. Additionally, they will receive meal plan ideas and shopping tips that will facilitate healthy and economical protein consumption up to or beyond their daily goal.
Study NCT03614351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control (CONT)
Description: Instructed not to alter their diet based on the app, and to continue to eat as they normally would.
Study NCT05181891 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Incentives for submitting negative-alcohol urine samples
Study NCT05498428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administrated by IV infusion.
Study NCT05498428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered by IV infusion.
Study NCT05498428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulant (DOAC)
Description: DOAC will be administered orally.
Study NCT05498428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Description: LMWH will be administered subcutaneously.
Study NCT06619314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: Oral Capsule
Study NCT06682260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG)
Description: Infusion of intravenous nitroglycerin beginning at 2 microgram/kg/min (2 ml/hour) and titrated with the aim of a MAP reduction of 20-30%. Infusion rate will not be increased after the first 30 minutes and is limited to 0.1 µg/kg/min to 5 µg/kg/min.
Study NCT06682676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal ventilation function test and cold and dry air nasal provocation test
Description: The visual analogue scale (VAS) of nasal symptoms, rhinoconjunctivitis quality of life questionnaire (RQLQ), total nasal symptom score (TNSS), total nasal volume (TNV), minimum cross-sectional area (MCA), peak inspiratory flow (PNIF), and total nasal resistance (TNR) at 75Pa were recorded before and after nasal ventilation function test and CDA nasal provocation test.
Study NCT06682130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A：Patients with PR or ctDNA positivity after salvage treatment
Description: 1. Immunotargeted therapy~   * Ottuzumab introvenous infusion, 1000mg day1;~  * Glofitamab introvenous infusion Group A: 2.5mg day8~2. Autologous stem cell transplantation SEAM regimen~   * Simustine 250mg/m2 orally, day1~  * Etoposide 200mg/m2 intravenous infusion, day2-5~  * Cytarabine 400mg/m2 intravenous infusion, day2-5~  * Metformin 140mg/m2 intravenous infusion, day6; Patients in Group A who intend to receive Glofitamab+ASCT will receive Glofitamab 2.5mg on day8 and start ASCT pretreatment on day15.
Study NCT06682130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B: Patients with CR and ctDNA negative after salvage treatment
Description: Group B patients initiated ASCT treatment directly after evaluating the efficacy of salvage treatment
Study NCT06682130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group C: Patients with SD/PD after posterior treatment
Description: 1. Immunotargeted therapy~   * Ottuzumab introvenous infusion, 1000mg day1;~  * Glofitamab introvenous infusion Group C: cycle1 2.5mg day8, 10mg day15 cycle2 30mg day21~2. Autologous stem cell transplantation SEAM regimen~   * Simustine 250mg/m2 orally, day1~  * Etoposide 200mg/m2 intravenous infusion, day2-5~  * Cytarabine 400mg/m2 intravenous infusion, day2-5~  * Metformin 140mg/m2 intravenous infusion, day6;~After two treatment cycles with Glofitamab, patients in group C had a PET-CT to assess efficacy. Those with partial remission proceeded to ASCT consolidation, those with complete remission chose between ASCT or Glofitamab maintenance, and those with stable disease or progressive disease exited the trial.
Study NCT05181891 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-contingent control
Description: Incentives for submitting urine samples
Study NCT05966142 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19
Study NCT06283563 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity tracking
Description: At the beginning, patients will be given a brief information about the benefits of exercise training. Additionally, a short brochure explaining the effects of exercise in MS will be given. Participants in the intervention group will be asked to join one of two groups created by the researchers via messaging app. Reminders will be arranged on Monday-Wednesday-Thursday in one of the groups, and on Tuesday-Thursday-Saturday in the other group. In this regard, it will be emphasized that he/she should exercise at least 3 days a week. In this regard, they will be encouraged to walk for at least 30 minutes, 3 days a week, on the days they determine. The total intervention period will be 8 weeks. Reminders to exercise will be given by the researchers in the created messaging app group. Patients will be reminded to take their mobile phones with them during physical activity and to record their daily exercise minutes.
Study NCT06283563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No physical activity tracking
Description: At the beginning, patients will be given a brief information about the benefits of exercise training. Additionally, a short brochure explaining the effects of exercise in multiple sclerosis will be given. Participants will be encouraged to continue their routine lives and no reminders will be given.
Study NCT06683937 — intervention group
Intervention type: OTHER
Intervention: Collection of data from the patient's medical file
Description: Collection of data from the patient's medical file
Study NCT06684015 — intervention group
Intervention type: DRUG
Intervention: İNTRATECHAL MORPHİNE GROUP
Description: Addition of intrathecal morphine as an adjuvant to local anesthesia in routine spinal anesthesia application and multimodal analgesia applications
Study NCT06684015 — intervention group
Intervention type: PROCEDURE
Intervention: Erector Spinae Plane Block
Description: Application of erector spinae plane block and multimodal analgesia applications at the end of the operation after routine spinal anesthesia application
Study NCT06683287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: red light and distant image screen
Description: red light plus distant image screen, children use these two devices at the same time
Study NCT06683287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: red light
Description: children use red light for 3 minutes each time, twice a day
Study NCT06683287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: distant image screen
Description: Children in this group were asked to use this device for ≥1 hour/day
Study NCT06683040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxacom
Description: Lyophilisate for solution for intravenous administration, 6.3 mg
Study NCT06683040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study NCT06684730 — intervention group
Intervention type: PROCEDURE
Intervention: Hand Function Assessment Scales
Description: The Disabilities of the Arm, Shoulder and Hand Questionnaire (DASH), The Box and Block Test (BBT) and Action Research Arm Test (ARAT) will be used as hand function assessment scales.
Study NCT06684730 — intervention group
Intervention type: OTHER
Intervention: Prosthesis Satisfaction Scale
Description: The Quebec Assistive Technology User Satisfaction Assessment (Q-YTKMD) Questionnaire will be used.
Study NCT06684730 — intervention group
Intervention type: OTHER
Intervention: Quality of Life Scale
Description: 5Q-5D-5L will be used as quality of life scale.
Study NCT05980975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee
Description: 4th hour, 8th hour and 12th hour of after the surgery, the patients in the coffee group received 10 gr. granulated coffee.
Study NCT05980975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot water
Description: hot water group were given 200 ml of 50-60 C0 sugar-free hot water at the 4th hour, 8th hour and 12th hour of after the operation
Study NCT05966142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Description: Genetic testing of CYP2D6 and CYP2C19
Study NCT05966142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decisions support
Description: Prescribing recommendations to the provider based on the pharmacogenetic testing results
Study NCT06684730 — intervention group
Intervention type: PROCEDURE
Intervention: Kinematic Analysis
Description: Kinematic analysis of shoulder abduction, elbow flexion, and cervical flexion will be performed during simulated tasks of drinking water from a glass and filling glass of water.
Study NCT06684730 — intervention group
Intervention type: PROCEDURE
Intervention: Parkour Completion Time
Description: A 10-item daily living activities parkour will be prepared for the participants. During the parkour, the participant will be given the following tasks: opening and closing 10 jar lids, slicing a 20cm cylindrical dough into 10 pieces, simulating drinking soup from a bowl 15 times with a spoon (standard bowl 150 ml, standard tablespoon 10 ml), simulating eating meatballs from a plate with a fork 10 times (approximately 6-10 meatballs per serving), simulating pouring water from a pitcher into a glass 10 times, simulating drinking water from a glass 10 times, simulating brushing teeth for 2 minutes, opening 10 clothespins attached to the edge of a cardboard box and attaching them to the other side, simulating opening and closing a zipper, and putting on shoes and tying shoelaces. The course completion time will be recorded.
Study NCT06684730 — intervention group
Intervention type: PROCEDURE
Intervention: Fatigue Scale
Description: A pre- and post-parkour will be employed, including a 5-point Likert scale for fatigue assesment, hand function assessment scales and kinematic analysis to participants. The results before and after the parkour will be compared.
Study NCT06684171 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiographic guidance
Description: After detailed evaluation, patients randomized in this group will undergo TEER procedure under guidance of fully echocardiography but any fluoroscopy in the entire process.
Study NCT06684171 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopic guidance
Description: After detailed evaluation, patients randomized in this group will undergo TEER procedure under combined guidance of echocardiography and fluoroscopy in the entire process.